- Non-Steroidal anti-inflammatory Drugs (NSAIDs)
- Disease modifying anti-rheumatic drugs (DMARDs)
- Conventional DMARD
- Biologic DMARD
Rheumatoid Arthritis Treatment Market size was valued at USD 22.9 billion in 2021, growing at a CAGR of 4.6% from 2022-28.Â This report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, global market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global rheumatoid arthritis treatment products. The World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of worldwide significance on January 30, 2020. Around 210 countries have been affected by COVID-19. Patients with rheumatoid arthritis who contract COVID-19 infection, according to the Lancet Rheumatology 2020, are at a high risk of developing severe symptoms and further consequences.Many DMARDs are in wide adoption as a first-line treatment for rheumatoid arthritis, such as sulphasalazine, methotrexate and hydroxychloroquine. Major companies like Can-Fite BioPharma Ltd. are investigating several novel antirheumatic disease modifying agents that are expected to be available in the market in the next 10 years, uptake of which by prescribers and patients would push market growth.
Fastest Growing Market
owing introduction of newer therapies into the market and availability of FDA approved biologic drugs such as rituximab, abatacept, etanercept, etc. are expected to fuel consumption of rheumatoid arthritis treatment market. Moreover, emerging economies are highly adopting towards novel technologies and therapies and increase in disposable income and products that are ready to get approval from FDA for the treatment of rheumatoid arthritis expected to propel the growth of the market. However, high costs associated with biological DMARD therapies may hinder the growth of the market over future years.Conventional DMARDs is the most common therapy for Rheumatoid Arthritis. These drugs are available in different dosage forms including oral as well as parenteral, each dosage form having a different treatment regime. Biological DMARD includes biologic agents that are approved for the treatment of rheumatoid arthritis. Any biologic treatment that is not approved by the regulatory authorities or is under investigation is beyond the scope of this report.
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.